Dendritic cells transduced with TEM8 recombinant adenovirus prevents hepatocellular carcinoma angiogenesis and inhibits cells growth

Vaccine

Volumn 28, Issue 43, 2010, Pages 7130-7135

  Yang, Xuemei ^a   Zhu, Huaping ^c   Hu, Zhangxue ^b  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

^c GENERAL HOSPITAL OF NORTHERN THEATER COMMAND   (China)

Author keywords

Adenovirus; Angiogenesis; Dendritic cells; Hepatocellular carcinoma cells; TEM8

Indexed keywords

ADENOVIRUS VECTOR; GAMMA INTERFERON; TUMOR ENDOTHELIAL MARKER 8; TUMOR MARKER; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; FEMALE; GENE TRANSFER; LIFESPAN; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR IMMUNITY; TUMOR VASCULARIZATION;

ADENOVIRIDAE; ANGIOGENESIS INHIBITORS; ANIMALS; CARCINOMA, HEPATOCELLULAR; DENDRITIC CELLS; FEMALE; LIVER NEOPLASMS; MICE; MICE, INBRED BALB C; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, CELL SURFACE; T-LYMPHOCYTES; TRANSDUCTION, GENETIC;

EID: 77957366060     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.07.014     Document Type: Article

References (40)

1. Cao X., Wang J., Zhang W., Chen G., Kong X., Tani K. Treatment of human hepatocellular carcinoma by fibroblast-mediated human interferon alpha gene therapy in combination with adoptive chemoimmunotherapy. J Cancer Res Clin Oncol 1995, 121(8):457-462.
2. Chan R.C., Xie Y. CD80 transfected human hepatocellular carcinoma cells activate cytotoxic T lymphocytes to target HCC cells with shared tumor antigens. Oncol Rep 2004, 12(2):435-442.
3. Dong H., Ge X., Shen Y., Chen L., Kong Y., Zhang H., et al. Gene expression profile analysis of human hepatocellular carcinoma using SAGE and LongSAGE. BMC Med Genomics 2009, 2:5.
4. Mao C.Y., Hua H.J., Chen P., Yu D.C., Cao J., Teng L.S. Combined use of chemotherapeutics and oncolytic adenovirus in treatment of AFP-expressing hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2009, 8(3):282-287.
5. Lee T.K., Castilho A., Ma S., Ng I.O. Liver cancer stem cells: implications for a new therapeutic target. Liver Int 2009, 29(7):955-965.
6. Blum H.E. Molecular therapy and prevention of hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2003, 2(1):11-22.
7. Izuishi K., Kato K., Ogura T., Kinoshita T., Esumi H. Remarkable tolerance of tumor cells to nutrient deprivation: possible new biochemical target for cancer therapy. Cancer Res 2000, 60(21):6201-6207.
8. Hu H., Chen D., Liu Y., Deng Y., Yang S., Qiao M., et al. Target ability and therapy efficacy of immunoliposomes using a humanized antihepatoma disulfide-stabilized Fv fragment on tumor cells. J Pharm Sci 2006, 95(1):192-199.
9. Casas A., Perotti C., Ortel B., Di Venosa G., Saccoliti M., Batlle A., et al. Tumor cell lines resistant to ALA-mediated photodynamic therapy and possible tools to target surviving cells. Int J Oncol 2006, 29(2):397-405.
10. Benouchan M., Do Nascimento F., Sebbah-Louriki M., Salzmann J.L., Crepin M., Perret G.Y., et al. Bystander cell killing spreading from endothelial to tumor cells in a three-dimensional multicellular nodule model after Escherichia coli nitroreductase gene delivery. Biochem Biophys Res Commun 2003, 311(4):822-828.
11. Loeper S., Romeike B.F., Heckmann N., Jung V., Henn W., Feiden W., et al. Frequent mitotic errors in tumor cells of genetically micro-heterogeneous glioblastomas. Cytogenet Cell Genet 2001, 94(1-2):1-8.
12. Dietmaier W., Gansbauer S., Beyser K., Renke B., Hartmann A., Rummele P., et al. Microsatellite instability in tumor and non-neoplastic colorectal cells from hereditary non-polyposis colorectal cancer and sporadic high microsatellite-instable tumor patients. Pathobiology 2000, 68(4-5):227-231.
13. Jouanneau J., Moens G., Bourgeois Y., Poupon M.F., Thiery J.P. A minority of carcinoma cells producing acidic fibroblast growth factor induces a community effect for tumor progression. Proc Natl Acad Sci USA 1994, 91(1):286-290.
14. Jouanneau J., Sato M., Arap W., Pasqualini R., Thiery J.P. Molecular targets on blood vessels for cancer therapies in clinical trials. Oncology (Williston Park, NY) 2007, 21(11):1346-1352. [discussion 54-5, 67, 70 passim].
15. Pramanik D., Majeti B.K., Mondal G., Karmali P.P., Sistla R., Ramprasad O.G., et al. Lipopeptide with a RGDK tetrapeptide sequence can selectively target genes to proangiogenic alpha5beta1 integrin receptor and mouse tumor vasculature. J. Med Chem 2008, 51(22):7298-7302.
16. Dome B., Magyar M. Tumor vasculature as a therapeutic target in non-small cell lung cancer. Magy Onkol 2008, 52(3):247-259.
17. Xiang R., Luo Y., Niethammer A.G., Reisfeld R.A. Oral DNA vaccines target the tumor vasculature and microenvironment and suppress tumor growth and metastasis. Immunol Rev 2008, 222:117-128.
18. St Croix B., Rago C., Velculescu V., Traverso G., Romans K.E., Montgomery E., et al. Genes expressed in human tumor endothelium. Science (New York, NY) 2000, 289(5482):1197-1202.
19. Carson-Walter E.B., Watkins D.N., Nanda A., Vogelstein B., Kinzler K.W., St Croix B. Cell surface tumor endothelial markers are conserved in mice and humans. Cancer Res 2001, 61(18):6649-6655.
20. Nanda A., Carson-Walter E.B., Seaman S., Barber T.D., Stampfl J., Singh S., et al. TEM8 interacts with the cleaved C5 domain of collagen alpha 3(VI). Cancer Res 2004, 64(3):817-820.
21. Hotchkiss K.A., Basile C.M., Spring S.C., Bonuccelli G., Lisanti M.P., Terman B.I. TEM8 expression stimulates endothelial cell adhesion and migration by regulating cell-matrix interactions on collagen. Exp Cell Res 2005, 305(1):133-144.
22. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature 1998, 392(6673):245-252.
23. Mallegol J., Van Niel G., Lebreton C., Lepelletier Y., Candalh C., Dugave C., et al. T84-intestinal epithelial exosomes bear MHC class II/peptide complexes potentiating antigen presentation by dendritic cells. Gastroenterology 2007, 132(5):1866-1876.
24. Almogy G., Lieberman S., Gips M., Pappo O., Edden Y., Jurim O., et al. Clinical outcomes of surgical resections for primary liver sarcoma in adults: results from a single centre. Eur J Surg Oncol 2004, 30(4):421-427.
25. Liu Z., Liu R., Qiu J., Yin P., Luo F., Su J., et al. Combination of human Fas (CD95/Apo-1) ligand with adriamycin significantly enhances the efficacy of antitumor response. Cell Mol Immunol 2009, 6(3):167-174.
26. Yamaguchi H., Shimizu M., Ban S., Koyama I., Hatori T., Fujita I., et al. Intraductal tubulopapillary neoplasms of the pancreas distinct from pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol 2009, 33(8):1164-1172.
27. Chiba T., Kamiya A., Yokosuka O., Iwama A. Cancer stem cells in hepatocellular carcinoma: recent progress and perspective. Cancer Lett 2009.
28. Kidner T., Dai M., Adusumilli P.S., Fong Y. Advances in experimental and translational research in the treatment of hepatocellular carcinoma. Surg Oncol Clin N Am 2008, 17(2):377-389.
29. Pang R.W., Poon R.T. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now. Oncology 2007, 72(Suppl. 1):30-44.
30. Chen B., Jin H., Wu K. Potential role of vascular targeted therapy to combat against tumor. Expert Opin Drug Deliv 2009, 6(7):719-726.
31. Kerbel R., Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev 2002, 2(10):727-739.
32. Kerbel R.S. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. Bioessays 1991, 13(1):31-36.
33. Bradley K.A., Mogridge J., Mourez M., Collier R.J., Young J.A. Identification of the cellular receptor for anthrax toxin. Nature 2001, 414(6860):225-229.
34. Nanda A., St Croix B. Tumor endothelial markers: new targets for cancer therapy. Curr Opin Oncol 2004, 16(1):44-49.
35. Ruan Z., Yang Z., Wang Y., Wang H., Chen Y., Shang X., et al. DNA vaccine against tumor endothelial marker 8 inhibits tumor angiogenesis and growth. J Immunother 2009, 32(5):486-491.
36. Dupont J., Latouche J.B., Ma C., Sadelain M. Artificial antigen-presenting cells transduced with telomerase efficiently expand epitope-specific, human leukocyte antigen-restricted cytotoxic T cells. Cancer Res 2005, 65(12):5417-5427.
37. Mizukoshi E., Nakamoto Y., Marukawa Y., Arai K., Yamashita T., Tsuji H., et al. Cytotoxic T cell responses to human telomerase reverse transcriptase in patients with hepatocellular carcinoma. Hepatology (Baltimore, MD) 2006, 43(6):1284-1294.
38. Adotevi O., Mollier K., Neuveut C., Cardinaud S., Boulanger E., Mignen B., et al. Immunogenic HLA-B*0702-restricted epitopes derived from human telomerase reverse transcriptase that elicit antitumor cytotoxic T-cell responses. Clin Cancer Res 2006, 12(10):3158-3167.
39. Diebold S.S., Cotten M., Koch N., Zenke M. MHC class II presentation of endogenously expressed antigens by transfected dendritic cells. Gene Ther 2001, 8(6):487-493.
40. Kaplan J.M., Yu Q., Piraino S.T., Pennington S.E., Shankara S., Woodworth L.A., et al. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens. J Immunol 1999, 163(2):699-707.